胸腺肽肠溶片联合艾拉莫德治疗类风湿性关节炎的效果及对患者炎症因子的影响

Effect of thymosin enteric-coated tablets combined with ilamod in the treatment of rheumatoid arthritis and its influence on inflammatory factors in patients

目的探讨胸腺肽肠溶片联合艾拉莫德治疗类风湿性关节炎的效果及对炎症因子的影响。方法选取2019年2月至2021年2月本院收治的88例类风湿性关节炎患者作为研究对象,根据治疗方法不同分为对照组与研究组,每组44例。对照组采用胸腺肽肠溶片治疗,研究组在对照组基础上联合艾拉莫德治疗,比较两组临床疗效、炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-6、IL-1β、C反应蛋白(CRP)]水平、实验室指标[关节肿胀数、关节疼痛数、视觉模拟评分法(VAS)]及骨代谢指标(受体活化因子配体、血清骨保护素)。结果研究组治疗总有效率为95.45%,高于对照组的81.82%,差异有统计学意义(P<0.05)。治疗前,两组TNF-α、IL-6、IL-1β、CRP水平比较差异无统计学意义;治疗后,两组TNF-α、IL-6、IL-1β、CRP水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组关节肿胀数、关节疼痛数、VAS评分比较差异无统计学意义;治疗后,两组关节肿胀数、关节疼痛数均少于治疗前,VAS评分均低于治疗前,且研究组关节肿胀数、关节疼痛数均少于对照组,VAS评分低于对照组,差异有统计学意义(P<0.05)。治疗前,两组受体活化因子配体、血清骨保护素水平比较差异无统计学意义;治疗后,两组受体活化因子配体水平均低于治疗前,血清骨保护素水平均高于治疗前,且研究组受体活化因子配体水平低于对照组,血清骨保护素水平高于对照组,差异有统计学意义(P<0.05)。结论胸腺肽肠溶片联合艾拉莫德治疗类风湿关节炎效果显著,可改善患者机体炎症及免疫指标,调节骨代谢,显著改善患者症状及病情,值得临床推广应用。

Objective To explore the effect of thymosin enteric-coated tablets combined with ilamod in the treatment of rheumatoid arthritis and its influence on inflammatory factors in patients.Methods 88 patients with rheumatoid arthritis admitted to our hospital from February 2019 to February 2021 were selected as the research subjects,and they were divided into the control group and the study group according to different treatment methods,with 44 cases in each group.The control group was treated with thymosin enteric-coated tablets,while the study group was treated with ilamod on the basis of the control group,the clinical efficacy,inflammatory factors(tumor necrosis factor-α[TNF-α],interleukin[IL]-6,IL-1β,C-reactive protein[CRP])and laboratory indicators(joint swelling,joint pain and visual analogue scale[VAS])and bone metabolism indicators(receptor activating factor ligand,serum osteoprotegerin)were compared between the two groups.Results The total effective rate in the study group was 95.45%,which was higher than 81.82%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of TNF-α,IL-6,IL-1βand CRP between the two groups;after treatment,the levels of TNF-α,IL-6,IL-1βand CRP of the two groups were lower than before treatment,and the study group was lower than the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in the number of joint swelling,joint pain and VAS score between the two groups;after treatment,the number of joint swelling and joint pain of the two groups were less than before treatment,and the scores of VAS was lower than before treatment,and the number of joint swelling and joint pain in the study group were less than those in the control group,and the scores of VAS was lower than that in the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of receptor activating factor ligand and serum osteoprotegerin between the two groups;after treatment,the levels of receptor activating factor ligand of the two groups were lower than those before treatment,the levels of serum osteoprotegerin were higher than that before treatment,and the levels of receptor activating factor ligand in the study group was lower than that in the control group,and the levels of serum osteoprotegerin was higher than that in the control group,and the differences were statistically significant(P<0.05).Conclusion Thymosin enteric-coated tablets combined with ilamod have significant effect on rheumatoid arthritis,which can improve the inflammatory and immune indexes of patients,regulate bone metabolism,and significantly improve the symptoms and condition of patients,which is worthy of clinical promotion and application.